Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of flavone lignan (+/-) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B

A technology of flavonoid lignans and uses, which is applied in the field of use of flavonoid lignans (±) Scutellaprostin A for preparing drugs for treating viral hepatitis B, can solve the problems that new uses have not been effectively developed, few documents, etc. The effect of large-scale production, convenient source, energy saving and emission reduction

Inactive Publication Date: 2012-03-28
DALI UNIV
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Although the flavonoid lignan compounds represented by silibinin have the above-mentioned antioxidant effects, there are relatively few literatures on their antiviral treatment
The new application of flavonoid lignans in the treatment of DNA virus infection, especially its anti-hepatitis B virus (including inhibition of HBsAg or HBeAg, inhibition of HBV DNA replication) has not been effectively developed

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of flavone lignan (+/-) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B
  • Application of flavone lignan (+/-) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B
  • Application of flavone lignan (+/-) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Example 1: Formula (1) (±)-trans-6-hydroxy-2-hydroxymethyl-3-(3-methoxy-4-hydroxyphenyl)-9-phenyl-2,3-dihydro-[1 , 4] Preparation instruments and reagents of dioxane [2,3-h] benzopyran-7-one:

[0033] The ultraviolet spectrum was measured with a Shimadzu UV-240 ultraviolet spectrophotometer; the hydrogen nuclear magnetic resonance spectrum 1 H-NMR is measured by INOVA type superconducting nuclear magnetic resonance spectrometer (VARIAN INOVA-400MHz) (tetramethylsilyl ether TMS is the internal standard); (100-200, 200-300 and 300-400 mesh) and silica gel GF254 (10-40 mesh) for thin-layer chromatography are produced by Qingdao Ocean Chemical Factory; all reagents used are analytically pure, thin-layer preparative chromatography (PTLC ) uses the aluminum foil silica gel plate of Merck Company; Sephadex LH-20 used for column chromatography adopts the product of Amersham Pharmacia Biotech AB Company of Sweden; Reversed-phase silica gel RP-18 adopts the Chromatorex product ...

Embodiment 2

[0040] Example 2: Inhibitory Effect of Compound (1) on Hepatitis B Surface Antigen (HBsAg) Secreted by HepG2.2.15 Cells

[0041] 2.1 Cell culture:

[0042] HepG2.2.15 cells were cultured in DMEM medium containing 10% inactivated fetal bovine serum, 100 U / ml penicillin and 100 U / ml streptomycin, 100 μg / ml G418 at 37°C, 5% CO 2 , cultured in an incubator with 100% relative humidity.

[0043] 2.2 The inhibitory effect of the compound of formula (1) on HepG2.2.15 cell growth was measured by MTT method:

[0044] Take the HepG2.2.15 cells in the logarithmic growth phase, and dilute the cells to 1×10 with medium 5 cells / ml, seeded in 96-well cell culture plate, 100 μl per well, at 37°C, 5% CO 2 After 24 hours in an incubator with 100% relative humidity, add compound (1) diluted with medium, the concentration is 1000 μg / ml, 200 μg / ml, 40 μg / ml and 8 μg / ml, 200 μg / ml in each well microliter, each concentration was set up in triplicate, placed at 37°C, 5% CO 2 , cultivated in an ...

Embodiment 3

[0053] Example 3: Inhibitory Effect of Compound (1) on Hepatitis B e Antigen (HBeAg) Secreted by HepG2.2.15 Cells

[0054] 3.1 Cell culture: the method is the same as in Example 2.

[0055] 3.2 Determination of the inhibitory effect of the compound of formula (1) on the growth of HepG2.2.15 cells by MTT method: the method is the same as in Example 2.

[0056] 3.3 Determination of the inhibitory effect of the compound on hepatitis B e antigen (HBeAg): take the HepG2.2.15 cells in the logarithmic growth phase, and dilute the cells to 1 × 10 with the medium 5 / ml, seeded in 96-well cell culture plate, 100ml per well, at 37°C, 5% CO 2 After culturing in an incubator with 100% relative humidity for 24 hours, add samples diluted with culture medium at concentrations of 20 μg / ml, 4 μg / ml and 0.8 μg / ml, 200 μl per well, and set three concentrations for each Multiple wells were placed at 37°C, 5% CO 2 , cultivated in an incubator with 100% relative humidity, change the culture med...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of flavone lignan (+ / -) Scutellaprostin A in preparing medicaments for treating viral hepatitis type B, in particular to a compound with the formula (1) or pharmaceutically-acceptable salts thereof for preparing medicaments for clearing HBsAg and HBeAg and suppressing HBV (Hepatitis B Virus) DNA replication. In the invention, the intensities of the compound for clearing the HBsAg and the HBeAg under the concentration of 20 micrograms / milliliter respectively reach 81.8 percent and 81.9 percent, which are respectively 5.1 times and 4.8 times as high as the corresponding activity of alpha-interferon used as a positive contrast medicament; and what is more exciting, when the compound has the concentration, the compound performs a suppression ratio higher than 81 percent, and the value is also higher than that of both lamivudine and alpha-interferon. Accordingly, the flavone lignan or the pharmaceutically-acceptable salts can be expectably used for preparing nucleoside medicaments for clearing the HBsAg and the HBeAg, suppressing the HBV DNA replication and treating HBV infected diseases.

Description

technical field [0001] The present invention relates to the technical field of medicine, in particular, the present invention relates to a kind of flavonoid lignan (±) Scutellaprostin A or pharmaceutically acceptable salt thereof of A cyclodioxane coupling type, which is used to prepare and reduce hepatitis B virus surface antigen HBsAg and hepatitis B Application of e antigen HBeAg, inhibiting HBV DNA replication, and treating hepatitis B virus infection diseases. This flavonoid lignan has extremely significant inhibition of HBsAg and HBeAg activity, and its intensity of removing HBsAg and HBeAg is as high as 81.8% and 81.9% respectively at the concentration of 20 micrograms / ml. Interferon) 5.1 times and 4.8 times the corresponding activity; more exciting is: at this concentration, it showed an inhibition rate greater than 81% to HBV DNA, higher than the positive control lamivudine, and is α-interference 2.1 times of the inhibitory rate of prime corresponding to HBV DNA. Th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/357A61P31/20
Inventor 申元英贾婕王建超杨雷香莫建霞巫秀美赵昱戴志明
Owner DALI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com